Tweet
Vaccine
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2010.10.023 | How to Cite or Link Using DOI
Copyright © 2010 Published by Elsevier Ltd.
Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
Purchase the full-text article
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Daniela Frascaa, 1, Alain Diaza, 1, Maria Romeroa, Ana Marie Landina, Mitch Phillipsa, Suzanne C. Lechnerb, John G. Ryanc and Bonnie B. Blomberga, Corresponding Author Contact Information, E-mail The Corresponding Author
a Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
b Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA
c Department of Family Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
Received 28 April 2010;
revised 16 August 2010;
accepted 10 October 2010.
Available online 23 October 2010.
Abstract
We have evaluated the serum response to seasonal influenza vaccination in subjects of different ages and associated this with the specific B cell response to the vaccine in vitro. Although the serum response has previously been shown to decrease with age, this has largely been associated to decreased T cell functions. Our results show that in response to the vaccine, the specific response of B cells in vitro, as measured by AID (activation-induced cytidine deaminase), the in vivo serum HI (hemagglutination inhibition) response, and the in vivo generation of switch memory B cells are decreased with age, as evaluated in the same subjects. This is the first report to demonstrate that intrinsic B cell defects with age contribute to reduced antibody responses to the influenza vaccine. The level of AID in response to CpG before vaccination can also predict the robustness of the vaccine response. These results could contribute to developing more effective vaccines to protect the elderly as well as identifying those most at risk.
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2010.10.023 | How to Cite or Link Using DOI
Copyright © 2010 Published by Elsevier Ltd.
Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
Purchase the full-text article
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Daniela Frascaa, 1, Alain Diaza, 1, Maria Romeroa, Ana Marie Landina, Mitch Phillipsa, Suzanne C. Lechnerb, John G. Ryanc and Bonnie B. Blomberga, Corresponding Author Contact Information, E-mail The Corresponding Author
a Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
b Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA
c Department of Family Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
Received 28 April 2010;
revised 16 August 2010;
accepted 10 October 2010.
Available online 23 October 2010.
Abstract
We have evaluated the serum response to seasonal influenza vaccination in subjects of different ages and associated this with the specific B cell response to the vaccine in vitro. Although the serum response has previously been shown to decrease with age, this has largely been associated to decreased T cell functions. Our results show that in response to the vaccine, the specific response of B cells in vitro, as measured by AID (activation-induced cytidine deaminase), the in vivo serum HI (hemagglutination inhibition) response, and the in vivo generation of switch memory B cells are decreased with age, as evaluated in the same subjects. This is the first report to demonstrate that intrinsic B cell defects with age contribute to reduced antibody responses to the influenza vaccine. The level of AID in response to CpG before vaccination can also predict the robustness of the vaccine response. These results could contribute to developing more effective vaccines to protect the elderly as well as identifying those most at risk.